Navigation Links
RetireSafe Urges Support for Provenge Prostate Cancer Treatment
Date:11/17/2010

BALTIMORE, Nov. 17, 2010 /PRNewswire-USNewswire/ -- RetireSafe, a 400,000-supporter strong national advocacy group for older Americans, today urged the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to support the full reimbursement of costs related to the important new Provenge treatment procedure for prostate cancer patients. RetireSafe President Thair Phillips urged the Committee to "consider not only the many Americans suffering from prostate cancer, and their families, but also the millions of older Americans who are not yet directly affected by the disease, but who will, nonetheless, be affected by this decision." He said, "These seniors care very deeply about the suffering and choices of the individuals who do have prostate cancer and also about the role of government in determining the availability of the best possible medical treatment."

"The MEDCAC decision today will have a lasting effect on future research and development of innovative new medications," Phillips continued. "If the Provenge treatment is denied for reimbursement, future innovation will suffer along with millions of cancer patients," he said.  "We second Dr. Allen Lichter, head of the American Society of Clinical Oncology, that it is 'extremely chilling' to innovation in cancer research if new FDA-approved treatments against cancer must now go through a second round of efficacy and safety review from CMS, even for 'on-label' use," Phillips stated.  "That kind of rationing, after the 15-year, $1 billion development of this state-of-the-art treatment, would be beyond cruel," Phillips charged.

"The clinical effectiveness of the Provenge treatment is not in dispute," he added.   "Whether the MEDCAC admits it or not the real core of this discussion is price, and price is the very thing that should not be a point of discussion," he stated.

"Finally, we see many new Food and Drug Administration (FDA) approved drugs and treatments applauded, while others, like the Provenge treatment for prostate cancer, are attacked for supposedly being too costly," he said. "This apparent bias is troubling to seniors and serves to break the trust seniors have in the agency that has a huge impact on their everyday lives," Phillips went on to say. "This decision impacts not only prostate patients but every American, especially older Americans, and MEDCAC should carefully consider the far reaching implications of this landmark decision," he concluded.


'/>"/>
SOURCE RetireSafe
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
2. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
3. DC Patients Cooperative Urges Changes to the Proposed Medical Cannabis Marijuana Regulations
4. Millennium Laboratories, Inc. Urges Medicare to Reconsider the 2010 Physician Reimbursement for Point-of-Care Urine Drug Screen Devices
5. FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
6. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
7. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
8. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
9. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
10. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
11. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):